ALNYLAM PHARMACEUTICALS INC's ticker is ALNY and the CUSIP is 02043Q107. A total of 475 filers reported holding ALNYLAM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,235,780,544 | +117296.2% | 9,407,871 | -1.1% | 2.33% | +18.6% |
| Q3 2022 | $1,904,474 | +31.0% | 9,514,758 | -4.6% | 1.96% | +31.7% |
| Q2 2022 | $1,453,896 | -12.2% | 9,968,434 | -1.7% | 1.49% | +28.4% |
| Q1 2022 | $1,655,716 | -8.0% | 10,139,729 | -4.5% | 1.16% | +17.5% |
| Q4 2021 | $1,800,388 | -8.5% | 10,616,751 | +1.9% | 0.99% | -4.0% |
| Q3 2021 | $1,966,605 | +13.5% | 10,415,784 | +1.9% | 1.03% | +21.8% |
| Q2 2021 | $1,733,319 | +21.9% | 10,224,859 | +1.5% | 0.84% | +6.2% |
| Q1 2021 | $1,422,484 | +19.8% | 10,074,963 | +10.3% | 0.80% | +20.4% |
| Q4 2020 | $1,186,941 | -8.3% | 9,132,422 | +2.7% | 0.66% | -25.8% |
| Q3 2020 | $1,294,600 | +1.1% | 8,891,488 | +2.8% | 0.89% | -8.7% |
| Q2 2020 | $1,280,956 | +39.9% | 8,648,678 | +2.8% | 0.98% | -1.6% |
| Q1 2020 | $915,621 | -2.9% | 8,411,769 | +2.7% | 0.99% | +8.9% |
| Q4 2019 | $942,865 | +42.4% | 8,186,723 | -0.6% | 0.91% | +21.0% |
| Q3 2019 | $662,336 | +46.9% | 8,235,974 | +32.6% | 0.75% | +57.5% |
| Q2 2019 | $450,850 | -15.1% | 6,213,470 | +9.3% | 0.48% | -17.7% |
| Q1 2019 | $531,217 | +53.5% | 5,684,504 | +19.8% | 0.58% | +29.1% |
| Q4 2018 | $346,093 | -11.4% | 4,746,850 | +6.4% | 0.45% | +6.6% |
| Q3 2018 | $390,587 | -6.3% | 4,462,826 | +5.5% | 0.42% | -6.2% |
| Q2 2018 | $416,798 | -8.7% | 4,231,881 | +10.4% | 0.45% | -16.0% |
| Q1 2018 | $456,656 | -0.5% | 3,834,213 | +6.2% | 0.54% | -6.0% |
| Q4 2017 | $458,779 | +14.7% | 3,611,014 | +6.0% | 0.57% | +12.4% |
| Q3 2017 | $400,099 | +46.2% | 3,405,392 | -0.8% | 0.51% | +37.8% |
| Q2 2017 | $273,681 | +60.1% | 3,431,316 | +2.9% | 0.37% | +47.8% |
| Q1 2017 | $170,894 | +37.6% | 3,334,511 | +0.5% | 0.25% | +22.1% |
| Q4 2016 | $124,227 | -45.6% | 3,318,022 | -1.5% | 0.20% | -42.9% |
| Q3 2016 | $228,305 | +21.4% | 3,368,325 | -0.6% | 0.36% | +6.2% |
| Q2 2016 | $188,125 | -11.3% | 3,390,252 | +0.3% | 0.34% | -9.9% |
| Q1 2016 | $212,159 | -17.4% | 3,379,935 | +23.9% | 0.37% | -16.6% |
| Q4 2015 | $256,790 | +350.5% | 2,727,734 | +284.6% | 0.45% | +299.1% |
| Q3 2015 | $56,995 | -39.9% | 709,250 | -10.4% | 0.11% | -34.5% |
| Q2 2015 | $94,907 | -11.2% | 791,750 | -22.6% | 0.17% | -15.3% |
| Q1 2015 | $106,866 | +0.8% | 1,023,430 | -6.4% | 0.20% | -5.2% |
| Q4 2014 | $106,062 | +14.0% | 1,093,430 | -8.2% | 0.21% | +4.4% |
| Q3 2014 | $93,011 | +23.6% | 1,190,930 | 0.0% | 0.20% | +25.2% |
| Q2 2014 | $75,231 | +4.4% | 1,190,930 | +11.0% | 0.16% | -4.1% |
| Q1 2014 | $72,027 | +25.4% | 1,072,800 | +20.1% | 0.17% | +25.0% |
| Q4 2013 | $57,453 | +19.2% | 893,100 | +18.6% | 0.14% | +11.5% |
| Q3 2013 | $48,200 | +72.5% | 753,000 | -16.4% | 0.12% | +43.5% |
| Q2 2013 | $27,938 | – | 900,900 | – | 0.08% | – |
Download | ||||||